1952 — Everest Medicines Share Price
- HK$6.38bn
- HK$4.43bn
- CNY125.93m
- 12
- 13
- 59
- 13
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.22 | ||
Price to Tang. Book | 2.47 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 47.94 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -17.04% | ||
Return on Equity | -15.9% | ||
Operating Margin | -740.67% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CNYm | n/a | n/a | 0.05 | 12.79 | 125.93 | 676.12 | 1,446.46 | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Everest Medicines Ltd is a China-based company principally engaged in the licensing, clinical development and commercialization of therapies to address critical unmet medical needs. The Company is focusing on the research and development of innovative drug candidate. The Company built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The Company mainly provides its products and services in Greater China and other emerging Asia Pacific markets.
Directors
- Wei Fu CHM (38)
- Ian Woo PRE (48)
- Kerry Blanchard CEO (65)
- Xiaofan Zhang COO (37)
- Xinhui Hu CTO (47)
- Jason Brown OTH (49)
- Kevin Guo OTH (51)
- Yang Shi OTH (45)
- Jennifer Yang OTH
- Xu Zhu OTH (50)
- Zhengying Zhu OTH (48)
- Yee Wa Lau SEC (48)
- Yubo Gong NED (35)
- Lan Kang NED (52)
- Shidong Jiang NID (53)
- Yifan Li NID (53)
- Bo Tan NID (47)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 1st, 2017
- Public Since
- October 9th, 2020
- No. of Employees
- 432
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Stock Exchange of Hong Kong Limited
- Shares in Issue
- 325,164,793
![Blurred out image of a map](https://www.stockopedia.com/assets/conversion/images/maps_placeholder.jpg)
- Address
- 16/F., CITIC Pacific Plaza,, SHANGHAI, 200041
- Web
- https://www.everestmedicines.com/
- Phone
- Contact
- Leah Liu
- Auditors
- PricewaterhouseCoopers
Upcoming Events for 1952
Similar to 1952
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 14:35 UTC, shares in Everest Medicines are trading at HK$19.96. This share price information is delayed by 15 minutes.
Shares in Everest Medicines last closed at HK$19.96 and the price had moved by +9.55% over the past 365 days. In terms of relative price strength the Everest Medicines share price has outperformed the FTSE Developed Asia Pacific Index by +4.83% over the past year.
The overall consensus recommendation for Everest Medicines is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Everest Medicines does not currently pay a dividend.
Everest Medicines does not currently pay a dividend.
Everest Medicines does not currently pay a dividend.
To buy shares in Everest Medicines you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$19.96, shares in Everest Medicines had a market capitalisation of HK$6.49bn.
Here are the trading details for Everest Medicines:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1952
Based on an overall assessment of its quality, value and momentum Everest Medicines is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Everest Medicines is HK$28.82. That is 44.38% above the last closing price of HK$19.96.
Analysts covering Everest Medicines currently have a consensus Earnings Per Share (EPS) forecast of -CNY2.22 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Everest Medicines. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +4.37%.
As of the last closing price of HK$19.96, shares in Everest Medicines were trading -9.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Everest Medicines PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$19.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Everest Medicines' management team is headed by:
- Wei Fu - CHM
- Ian Woo - PRE
- Kerry Blanchard - CEO
- Xiaofan Zhang - COO
- Xinhui Hu - CTO
- Jason Brown - OTH
- Kevin Guo - OTH
- Yang Shi - OTH
- Jennifer Yang - OTH
- Xu Zhu - OTH
- Zhengying Zhu - OTH
- Yee Wa Lau - SEC
- Yubo Gong - NED
- Lan Kang - NED
- Shidong Jiang - NID
- Yifan Li - NID
- Bo Tan - NID